uu.seUppsala University Publications
Change search
ReferencesLink to record
Permanent link

Direct link
The use of granulocyte colony stimulating factor (G-CSF) and management of chemotherapy delivery during adjuvant treatment for early-stage breast cancer-Further observations from the IMPACT solid study
Univ Tampere, Tampere Univ Hosp, FIN-33101 Tampere, Finland..
Chania Gen Hosp, Khania, Greece..
Orbis Med Ctr, Sittard, Netherlands..
Brust Zentrum Zurich, Zurich, Switzerland..
Show others and affiliations
2016 (English)In: Breast, ISSN 0960-9776, E-ISSN 1532-3080, Vol. 25, 27-33 p.Article in journal (Refereed) PublishedText
Abstract [en]

Objective: To investigate the use and impact of granulocyte colony-stimulating factors (G-CSF) on chemotherapy delivery and neutropenia management in breast cancer in a clinical practice setting. Methods: IMPACT Solid was an international, prospective observational study in patients with a physician-assessed febrile neutropenia (FN) risk of >= 20%. This analysis focused on stages I-III breast cancer patients who received a standard chemotherapy regimen for which the FN risk was published. Chemotherapy delivery and neutropenia-related outcomes were reported according to the FN risk of the regimen and intent of G-CSF use. Results: 690 patients received a standard chemotherapy regimen; 483 received the textbook dose/schedule with a majority of these regimens (84%) having a FN risk >= 10%. Patients receiving a regimen with a FN risk >= 10% were younger with better performance status than those receiving a regimen with a FN risk < 10%. Patients who received higher-risk regimens were more likely to receive G-CSF primary prophylaxis (48% vs 22%), complete their planned chemotherapy (97% vs 88%) and achieve relative dose intensity >= 85% (93% vs 86%) than those receiving lower-risk regimens. Most first FN events (56%) occurred in cycles not supported with G-CSF primary prophylaxis. Conclusion: Physicians generally recommend standard adjuvant chemotherapy regimens and were more likely to follow G-CSF guidelines for younger, good performance status patients in the curative setting, and often modify standard regimens in more compromised patients. However, G-CSF support is not optimal, indicated by G-CSF primary prophylaxis use in < 50% of high-risk patients and observation of FN without G-CSF support.

Place, publisher, year, edition, pages
2016. Vol. 25, 27-33 p.
Keyword [en]
Granulocyte colony-stimulating factor, Neutropenia, Chemotherapy delivery, Clinical practice
National Category
Cancer and Oncology
URN: urn:nbn:se:uu:diva-277777DOI: 10.1016/j.breast.2015.11.007ISI: 000368373500004PubMedID: 26801413OAI: oai:DiVA.org:uu-277777DiVA: diva2:905823
Available from: 2016-02-23 Created: 2016-02-23 Last updated: 2016-02-23Bibliographically approved

Open Access in DiVA

No full text

Other links

Publisher's full textPubMed

Search in DiVA

By author/editor
Lindman, Henrik
By organisation
Experimental and Clinical Oncology
In the same journal
Cancer and Oncology

Search outside of DiVA

GoogleGoogle Scholar
The number of downloads is the sum of all downloads of full texts. It may include eg previous versions that are now no longer available

Altmetric score

Total: 24 hits
ReferencesLink to record
Permanent link

Direct link